NASDAQ · SLNO
Healthcare · Biotechnology
$53.01
Up+$0.00 (+0.00%)
Updated Sep 10, 2026, 9:21 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
SLNO does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning SLNO.
SLNO research
Company profile and research snapshot.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | Equal-Weight | — |
| Apr 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Apr 7, 2026 | Wolfe Research | Peer Perform | — |
| Apr 7, 2026 | TD Cowen | Hold | — |
| Apr 6, 2026 | Cantor Fitzgerald | Neutral | — |
No generated briefing is available yet.
Benzinga · Feb 27, 2026
Wells Fargo analyst Derek Archila maintains Soleno Therapeutics (NASDAQ:SLNO) with a Overweight and lowers the price target from $114 to $110.
Yahoo · Feb 26, 2026
Health care stocks declined late Thursday afternoon with the NYSE Health Care Index easing 0.1% and
Yahoo · Feb 26, 2026
Moby summary of Soleno Therapeutics, Inc.'s Q4 2025 earnings call
Benzinga · Feb 26, 2026
TD Cowen analyst Tyler Van Buren maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and lowers the price target from $120 to $85.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SLNO.
